FRESENIUS KABI

Press Release

Matthias Link
Corporate Communications

Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
matthias.link@fresenius.com
www.fresenius.com

January 13, 2010

Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation® Technology

Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have extended their collaboration in the field of HESylation® Technology. The companies started their cooperation in May 2009 and now have entered into the next phase of development. The extension of the collaboration is combined with a further payment to Fresenius Kabi.

Under the Research, Development and License Agreement, Fresenius Kabi has licensed its proprietary HESylation® Technology to Bayer Schering Pharma. This technology platform is based on hydroxyethyl starch ("HES") and may allow the prolongation of the active half-life of proteins.

Fresenius Kabi is responsible for supporting Bayer Schering Pharma with respect to implementing HESylation Technology and providing the appropriate HES derivative to Bayer Schering Pharma. Under the agreement, Bayer Schering Pharma oversees the development and commercialization. Fresenius Kabi will receive milestone payments as well as royalties on sales for licensing of the HESylation® Technology.

HESylation® Technology

HESylation® Technology allows a targeted modification of drugs and their characteristics by site-specific coupling to HES molecules. HES-coupling enables the modification of key pharmacological parameters such as absorption, metabolization, half-life, water solubility and safety.

Fresenius Kabi's Business Unit HESylation® Technology is a focused team of experienced professionals. With access to customized HES species and dedicated fully equipped R&D and GMP facilities the support for biopharmaceutical product developments are fulfilled at highest standards.

HESylation® Technology is based on the extensive expertise in the field of hydroxyethyl starch ("HES") that Fresenius Kabi has gathered as the world's largest producer of pharmaceutical grade HES. HES is derived from waxy maize starch and can be metabolized by the body's enzymes. HES solutions have been safely administered for over 30 years to treat deficient blood volume and to improve the rheological properties of blood.

Fresenius Kabi expects to enter into further collaborations with leading pharmaceutical and biotechnology companies to contribute to improved pharmaceutical products through its HESylation® Technology platform.

HESylation® Technology is covered by a broad portfolio of intellectual property rights. For further details please visit http://www.HESylation.com.

# # #

Fresenius Kabi

Fresenius Kabi is focused on products for the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume substitution and intravenously administered drugs as well as parenteral and enteral nutrition and the medical devices for the application.

Fresenius Kabi has more than 20,000 employees worldwide and a global network of around 55 sales organizations and more than 55 production sites. In 2008, Fresenius Kabi achieved sales of € 2,495 million and an operating profit (EBIT) of € 443 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.
For more information about Fresenius Kabi, please visit the company's web site at www.fresenius-kabi.com

Contact for BU HESylation® Technology:
Frank Feller, Commercial Affairs & Business Development
Kabi Innovation Centre
Fresenius Kabi Deutschland GmbH
T: +49 6172 686 8558
F: +49 6172 686 390033
Email: hesylation@fresenius-kabi.com
www.HESylation.com

proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.